Skip to content
← Full study record

NCT03357952 · MORE INFO

Limitations, agreements, and source contact

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma · Source last updated 2025-02-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Single participant enrolled in Part 2 was not evaluable for efficacy, hence data for Part 2 efficacy outcome measures was not collected. Sponsor suspended enrollment during Part 2, hence Part 2 stopped early, and Part 3 was not conducted.
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
phone
844-434-4210
title
Executive Medical Director
Complete source fields
certain Agreement
other Details
If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Single participant enrolled in Part 2 was not evaluable for efficacy, hence data for Part 2 efficacy outcome measures was not collected. Sponsor suspended enrollment during Part 2, hence Part 2 stopped early, and Part 3 was not conducted.
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
phone
844-434-4210
title
Executive Medical Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice